The Combination of GX-188E Vaccination and Pembrolizumab in Patients With HPV 16 and/or 18+ Advanced Cervical Cancer
A Multi-Center, Open-label Phase Ib-II Trial of the Combination of GX-188E Vaccination and Pembrolizumab in Patients With Advanced, Non-Resectable HPV Type 16 and/or 18 Positive Cervical Cancer
Sponsor: Genexine, Inc.
A PHASE1/PHASE2 clinical study on Cervical Cancer, this trial is completed. The trial is conducted by Genexine, Inc. and has accumulated 14 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Aug 2025 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Aug 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Apr 2024 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
Status: Unknown Status → Completed
▶ Show 9 earlier versions
-
Mar 2024 — Apr 2024 [monthly]
Unknown Status PHASE1_PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jun 2022 — Mar 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
May 2022 — Jun 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — May 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Aug 2020 — Sep 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2018 — Aug 2020 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — Sep 2018 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Genexine, Inc.
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .